July 1, 2013 Alzheimer’s Disease Public-Private Partnerships: A Landscape of the Global Nonprofit Community
May 30, 2013 Identifying Combinatorial Biomarkers by Association Rule Mining in the CAMD Alzheimer’s Database
March 17, 2013 Development of a patient-reported outcome (PRO) instrument to assess complex activities of daily living and interpersonal functioning in patients with mild cognitive impairment due to suspected Alzheimer’s disease: the qualitative research phase
March 1, 2013 The advantages of frontotemporal degeneration drug development (Part 2 of frontotemporal degeneration: the next therapeutic frontier)
March 1, 2013 Global standardization measurement of cerebral spinal fluid for Alzheimer’s disease: an update from the Alzheimer’s Association Global Biomarkers Consortium
January 1, 2013 Understanding Placebo Responses in Alzheimer’s Disease Clinical Trials from the Literature Meta-Data and CAMD Database
December 23, 2012 Research and standardization in Alzheimer’s trials: reaching international consensus
November 29, 2012 C-Path Cosponsors Workshop on Combination Drug Development for Alzheimer’s Disease Combination therapy development has been successful in other life-threatening diseases in part because collaborative approaches we
January 10, 2012 Combining Patient-level And Summary-level Data For Alzheimer’s Disease Modeling And Simulation: A Β Regression Meta-analysis
May 16, 2012 Stakeholders Share Data to Design Better Trials for Neurodegenerative Diseases The Coalition Against Major Diseases is pooling clinical data to build disease and drug models.
